MedTrace Logo

To Evaluate Efficacy, Safety, and Tolerability of KX-826 in Male Subjects With Androgenetic Alopecia

NCT05218642 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 123

Last updated 2023-11-22

No results posted yet for this study

Summary

The study is a randomized, double-blind, placebo-controlled, parallel group, phase 2 study to evaluate the efficacy, safety and tolerability of KX-826 in male subjects with androgenetic alopecia.

Conditions

Interventions

DRUG

KX- 826 dosed at 2.5mg

2.5mg of the investigational drug to be applied topically to scalp twice daily for 24 weeks

DRUG

KX-826 dosed at 5mg

5mg of the investigational drug to be applied topically to scalp once daily for 24 weeks

DRUG

KX-826 dosed at 5mg

5mg of the investigational drug to be applied topically to scalp twice daily for 24 weeks

DRUG

Matching placebo to KX-826

Placebo applied topically to scalp twice daily or once daily for 24 weeks

Sponsors & Collaborators

  • Suzhou Kintor Pharmaceutical Inc,

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2022-01-31
Primary Completion
2023-02-13
Completion
2023-02-13
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05218642 on ClinicalTrials.gov